853796-39-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-methyl-benzeneacetic acid is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be a versatile building block for the development of new medications with potential therapeutic applications.
Used in Agricultural Industry:
Due to its antibacterial and antifungal properties, 4-Bromo-2-methyl-benzeneacetic acid is used as an active ingredient in agricultural chemicals to protect crops from diseases and pests, thereby enhancing crop yield and quality.
Used in Research:
4-Bromo-2-methyl-benzeneacetic acid is utilized in research settings for the study of chemical reactions and the development of new synthetic methods. Its reactivity and structural features make it a valuable compound for exploring novel chemical pathways and understanding the mechanisms of various reactions.

Upstream product

• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 17100-58-2 4-bromo-2-methylbenzyl alcohol 
• 24078-15-7 4-bromo-1-(chloromethyl)-2-methylbenzene 
• 215800-05-8 2-(4-bromo-2-methylphenyl)acetonitrile 
• 1037088-26-8 1-allyl-4-bromo-2-methylbenzene 
• 116632-39-4 2-methyl-4-bromoiodobenzene 
• 15852-73-0 (3-Bromophenyl)methanol 

Downstream Products

• 1415960-54-1 methyl 2-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 
• 958646-47-4 (4-bromo-2-methylphenyl)acetic acid methyl ester 
• 1037082-12-4 (R)-2-(4-bromo-2-methylphenyl)propan-1-ol 
• 1037082-18-0 (R)-(2-(4-bromo-2-methylphenyl)propoxy)(tert-butyl)dimethylsilane 
• 1037082-19-1 (R)-(4-(1-((tert-butyldimethylsilyl)oxy)propan-2-yl)-3-methylphenyl)boronic acid 

Relevant academic research and scientific papers

Aromatic Claisen Rearrangements of Benzyl Ketene Acetals: Conversion of Benzylic Alcohols to (ortho-Tolyl)acetates

Claisen rearrangements of benzyl vinyl ethers are much less facile than those of aliphatic allyl vinyl ethers, and their synthetic utility has remained relatively unexplored. A one-pot procedure is reported for the generation and Claisen rearrangement of benzyl vinyl ethers that contain an activating α-alkoxy substituent on the vinyl group. A [3,3]-sigmatropic mechanism was supported by trapping of the intermediate isotoluene in an intramolecular Alder–ene reaction.

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors

Incorporation of a methyl group onto a macrocyclic FVIIa inhibitor improves potency 10-fold but is accompanied by atropisomerism due to restricted bond rotation in the macrocyclic structure, as demonstrated by NMR studies. We designed a conformational constraint favoring the desired atropisomer in which this methyl group interacts with the S2 pocket of FVIIa. A macrocyclic inhibitor incorporating this constraint was prepared and demonstrated by NMR to reside predominantly in the desired conformation. This modification improved potency 180-fold relative to the unsubstituted, racemic macrocycle and improved selectivity. An X-ray crystal structure of a closely related analogue in the FVIIa active site was obtained and matches the NMR and modeled conformations, confirming that this conformational constraint does indeed direct the methyl group into the S2 pocket as designed. The resulting rationally designed, conformationally stable template enables further optimization of these macrocyclic inhibitors.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.